leaptx.com (LPTX) - שולי רווח גולמי ממכירות

The average gross margin reflects the financial standing of Leap Therapeutics, Inc. (LPTX), which develops antibodies for gastrointestinal therapy without current operating profit. The value of 0.00 represents the current figure for this metric. The development of DKN-01 establishes a unique intellectual property base for the company, yet testing costs are creating a liquidity deficit and necessitating a constant influx of external financing to cover negative cash flow.
פילוחים אנליטיים ודוחות נתונים של חברת Leap Tx (LPTX)

Leap Therapeutics, Inc. (LPTX) focuses on developing innovative antibodies for targeted oncology, making the gross sales margin a key performance indicator for the commercialization of the DKN-01 drug. This metric is calculated as the portion of revenue minus direct production costs, allowing investors to assess the business's internal profitability and the company's ability to generate excess capital for further scaling of development.